Parents' attitude toward multiple vaccinations at a single visit with alternative delivery methods.

abstract：:Various glycoprotein conjugate vaccines have been developed for the prevention of invasive meningococcal disease, having significant advantages over pure polysaccharide vaccines. One of the most important features of the conjugate vaccines is the induction of a T-cell dependent immune response, which enables both the ...

journal_title：Human vaccines & immunotherapeutics

authors： Bröker M,Berti F,Costantino P

更新日期：2016-07-02 00:00:00

abstract：:Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT00468858). We describe cell-mediated immune (CMI) responses; safety and ...

journal_title：Human vaccines & immunotherapeutics

authors： Moris P,Bauer KM,Currier JR,Friberg H,Eckels KH,Esquilin IO,Gibbons RV,Innis BL,Jarman RG,Simasathien S,Sun P,Thomas SJ,Watanaveeradej V

更新日期：2019-01-01 00:00:00

abstract：:Control programs for emerging influenza are in urgent need of novel therapeutic strategies to mitigate potentially devastating threats from pathogenic strains with pandemic potential. Current vaccines and antivirals have inherent limitations in efficacy, especially with rapid evolutionary changes of influenza viruses....

journal_title：Human vaccines & immunotherapeutics

authors： Berry CM

更新日期：2018-03-04 00:00:00

abstract：:Dynamically changing social situation associated with migrations, increasing freedom rights, popularity of anti-vaccine movements and the resulting from that decrease in herd immunity, forces the medical society and the governments of various countries to reflect on the attitude toward vaccinations. Issues of freedoms...

journal_title：Human vaccines & immunotherapeutics

authors： Patryn RK,Zagaja A

更新日期：2016-08-02 00:00:00

abstract：:Italy was one of the first countries in the world to introduce a routine vaccination program against HBV for newborns and 12-y-old children. From a clinical point of view, such strategy was clearly successful. The objective of our study was to verify whether, at 20 y from its implementation, hepatitis B universal vacc...

journal_title：Human vaccines & immunotherapeutics

authors： Boccalini S,Taddei C,Ceccherini V,Bechini A,Levi M,Bartolozzi D,Bonanni P

更新日期：2013-05-01 00:00:00

abstract：:Archaeosomes are liposomes formulated using total polar lipids (TPLs) or semi-synthetic glycolipids derived from archaea. Conventional archaeosomes with entrapped antigen exhibit robust adjuvant activity as demonstrated by increased antigen-specific humoral and cell-mediated responses and enhanced protective immunity ...

journal_title：Human vaccines & immunotherapeutics

authors： Agbayani G,Jia Y,Akache B,Chandan V,Iqbal U,Stark FC,Deschatelets L,Lam E,Hemraz UD,Régnier S,Krishnan L,McCluskie MJ

更新日期：2020-09-01 00:00:00

abstract：:Varicella live attenuated vaccine led to a significant reduction in morbidity and mortality from varicella zoster disease. Vaccine adverse effects are mostly mild. Immunosuppression is the main risk factor for severe varicella. Risk factors for disease following vaccination are less studied. We report a 12-month-old i...

journal_title：Human vaccines & immunotherapeutics

authors： Swed-Tobia R,Kassis I,Hanna S,Szwarcwort-Cohen M,Dovrat S,Dabaja-Younis H

更新日期：2020-09-18 00:00:00

abstract：:Pneumococci are capable of vaccine escape by genetic recombination at the targeted capsular locus, significantly reducing long-term vaccine effectiveness. Recently, efforts have been redirected to understanding pneumococcal biology related to potential next-generation vaccine candidates. A variety of serotype-independ...

journal_title：Human vaccines & immunotherapeutics

authors： Abry MF,Kimenyi KM,Osowo FO,Odhiambo WO,Sewe SO,Kulohoma BW

更新日期：2015-01-01 00:00:00

abstract：:Japanese encephalitis virus is the major cause of encephalitis in India. To control the increasing incidence and fatal outbreaks, SA 14-14-2 vaccine was introduced initially in 104 endemic districts in phased manner from 2006 to 2011. As there is no data available before 2008 on the number of Japanese encephalitis (JE...

journal_title：Human vaccines & immunotherapeutics

authors： Muniaraj M,Rajamannar V

更新日期：2019-01-01 00:00:00

abstract：:DNA vaccination holds the potential to treat or prevent nearly any immunogenic disease, including cancer. To date, these vaccines have demonstrated limited immunogenicity in vivo due to the absence of a suitable delivery system which can protect DNA from degradation and improve transfection efficiencies in vivo. Recen...

journal_title：Human vaccines & immunotherapeutics

authors： Cole G,McCaffrey J,Ali AA,McBride JW,McCrudden CM,Vincente-Perez EM,Donnelly RF,McCarthy HO

更新日期：2017-01-02 00:00:00

abstract：:The 7th Asian Vaccine Conference (ASVAC 2019) was held in Yangon, Myanmar from 13 to 15, September 2019. It brought together stakeholders in the field of vaccination to address challenges and issues relevant to clinical practice and immunization programs in the region. The conference themed "Immunization: sustaining h...

journal_title：Human vaccines & immunotherapeutics

authors： Linn K,Bravo L,Goh DYT,Nelson EAS

更新日期：2020-07-02 00:00:00

abstract：INTRODUCTION:Enterovirus A71(EV-A71)-associated hand, foot, and mouth disease (HFMD) has been reported worldwide, and poses a particularly heavy burden on patients, families, and society in China. Three Chinese companies have licensed inactivated EV-A71 vaccines, all of which have demonstrated good efficacy for prevent...

journal_title：Human vaccines & immunotherapeutics

authors： Wang X,An Z,Huo D,Jia L,Li J,Yang Y,Liang Z,Wang Q,Wang H

更新日期：2019-01-01 00:00:00

abstract：:The usual treatments for patients with non-small-cell lung cancer (NSCLC), such as advanced lung adenocarcinoma, are unspecific and aggressive, and include lung resection, radiotherapy and chemotherapy. Recently, treatment with monoclonal antibodies and biological inhibitors has emerged as an effective alternative, ge...

journal_title：Human vaccines & immunotherapeutics

authors： Silva AP,Coelho PV,Anazetti M,Simioni PU

更新日期：2017-04-03 00:00:00

abstract：:DC-based therapeutic vaccines as a promising strategy against chronic infections and cancer have been validated in several clinical trials. However, DC-based vaccines are complex and require many in vitro manipulations, which makes this a personalized and expensive therapeutic approach. In contrast, DNA-based vaccines...

journal_title：Human vaccines & immunotherapeutics

authors： Li J,Valentin A,Beach RK,Alicea C,Felber BK,Pavlakis GN

更新日期：2015-01-01 00:00:00

abstract：:The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of...

journal_title：Human vaccines & immunotherapeutics

authors： Silfverdal SA,Assudani D,Kuriyakose S,Van Der Meeren O

更新日期：2014-01-01 00:00:00

abstract：:Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publications describing antib...

journal_title：Human vaccines & immunotherapeutics

authors： Chilson E,Scott DA,Schmoele-Thoma B,Watson W,Moran MM,Isturiz R

更新日期：2020-11-01 00:00:00

abstract：:Anflu® is a seasonal trivalent inactivated split-virion influenza vaccine manufactured by Sinovac Biotech Co., Ltd. The objectives of this study were to evaluate the safety of Anflu® (2013-14 formulation: H1N1, H3N2 and BYAM) in infants and adults and its immunogenicity and cross-reactivity against mismatched influenz...

journal_title：Human vaccines & immunotherapeutics

authors： Shen Y,Hu Y,Meng F,Du W,Li W,Song Y,Ji X,Huo L,Fu Z,Yin W

更新日期：2016-05-03 00:00:00

abstract：:This was a randomized, placebo-controlled, Phase I/II study conducted in a Japanese cohort to assess the safety and immunogenicity of Clostridium difficile vaccine (the same formulation as that used in the ongoing global Phase III study). Healthy Japanese adults aged 40-75 years were randomized to receive either C. di...

journal_title：Human vaccines & immunotherapeutics

authors： Matsuoka O,Patel DM,Sasaki S,Oka H,Sasaki T,Pietrobon PJ,Laot T,Bouckenooghe A,Menezes J,de Bruyn G

更新日期：2018-02-01 00:00:00

abstract：:Allergen-specific IgG produced by immune mothers is associated with less predisposition to allergy development in their children. This finding has been described by several groups over the last few decades, but the mechanisms by which maternal IgG can inhibit allergy development are still not fully understood. With th...

journal_title：Human vaccines & immunotherapeutics

authors： Victor JR

更新日期：2017-03-04 00:00:00

abstract：:HIV sequence diversity and the propensity of eliciting immunodominant responses targeting inessential variable regions are hurdles in the development of an effective AIDS vaccine. We developed a DNA vaccine comprising conserved elements (CE) of SIV p27Gag and HIV-1 Env and found that priming vaccination with CE DNA is...

journal_title：Human vaccines & immunotherapeutics

authors： Hu X,Lu Z,Valentin A,Rosati M,Broderick KE,Sardesai NY,Marx PA,Mullins JI,Pavlakis GN,Felber BK

更新日期：2018-01-01 00:00:00

abstract：:Hepatitis A is a vaccine-preventable infection caused by the HA virus (HAV) with transitional to intermediate endemicity in China. An inactivated vaccine first licensed in China in 2010 (Avaxim® 80U Pediatric) is indicated for primary and booster vaccination in children from 12 months to 15 years of age. This Phase IV...

journal_title：Human vaccines & immunotherapeutics

authors： Shi N,Rasuli A,Thollot Y

更新日期：2019-01-01 00:00:00

abstract：:Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This is a review dedicated to determine major regulatory and developmental issues around cancer immunotherapeutics. A three pillar approach should be used in setting a development path: discovery platforms and suffi...

journal_title：Human vaccines & immunotherapeutics

authors： Kudrin A

更新日期：2012-09-01 00:00:00

abstract：:Maternal immunization has the potential to reduce the burden of infectious diseases in the pregnant woman and her infant. Many countries now recommend immunization against influenza at any stage of pregnancy and against pertussis in the third trimester. Despite evidence of the safety and effectiveness of these vaccine...

journal_title：Human vaccines & immunotherapeutics

authors： Marshall H,McMillan M,Andrews RM,Macartney K,Edwards K

更新日期：2016-04-02 00:00:00

abstract：:A universal vaccine that provides long-lasting protection from both epidemic and pandemic influenza viruses remains the "holy grail" of influenza vaccine research. Though virus neutralization assays are the current benchmark of measuring vaccine effectiveness, it is clear that Fc-receptor functions can drastically imp...

journal_title：Human vaccines & immunotherapeutics

authors： Jegaskanda S,Vanderven HA,Wheatley AK,Kent SJ

更新日期：2017-06-03 00:00:00

abstract：:The multicomponent meningococcal serogroup B vaccine, 4CMenB, has demonstrated effectiveness in preventing invasive MenB disease in infants and in controlling MenB outbreaks. The need for/timing of additional booster doses is not yet established. We reviewed eight studies that evaluated antibody persistence and booste...

journal_title：Human vaccines & immunotherapeutics

authors： Martinón-Torres F,Nolan T,Toneatto D,Banzhoff A

更新日期：2019-01-01 00:00:00

abstract：:Dendritic cells (DCs) are known to be a set of morphology, structure and function of heterogeneous professional antigen presenting cells (APCs), as well as the strongest functional antigen presenting cells, which can absorb, process and present antigens. As the key regulators of innate and adaptive immune responses, D...

journal_title：Human vaccines & immunotherapeutics

authors： Chen P,Liu X,Sun Y,Zhou P,Wang Y,Zhang Y

更新日期：2016-03-03 00:00:00

abstract：:A task group was formed with the aim to improve the quality of the service offered by ensuring that all children waiting for an appointment for vaccination would be offered one at the earliest opportunity. Children aged between 12 mo-5 y that were not completely immunized for their age were identified and included in ...

journal_title：Human vaccines & immunotherapeutics

authors： Falconer MA

更新日期：2013-06-01 00:00:00

abstract：OBJECTIVES:Economic evaluations on influenza vaccination from low resource settings are scarce and have not been evaluated using a systematic approach. Our objective was to conduct a systematic review on the value for money of influenza vaccination in low- and middle-income countries. METHODS:PubMed and EMBASE were se...

journal_title：Human vaccines & immunotherapeutics

authors： Ott JJ,Klein Breteler J,Tam JS,Hutubessy RC,Jit M,de Boer MR

更新日期：2013-07-01 00:00:00

abstract：:For the 2010/11 influenza season the prenatal vaccination program was extended to all women in England and Wales irrespective of gestational age--this was a considerable shift in practice for both pregnant women and healthcare providers where the emphasis previously had been only on targeted vaccination for pregnant w...

journal_title：Human vaccines & immunotherapeutics

authors： Baxter D

更新日期：2013-06-01 00:00:00

abstract：:Neisseria meningitidis serogroup B (MnB) is a significant cause of invasive meningococcal disease, but no broadly protective vaccine is yet approved. We assessed the safety and immunogenicity of a bivalent MnB vaccine composed of lipidated subfamily A and B variants of recombinant LP2086 (rLP2086, also known as factor...

journal_title：Human vaccines & immunotherapeutics

authors： Sheldon EA,Schwartz H,Jiang Q,Giardina PC,Perez JL

更新日期：2012-07-01 00:00:00